INTRODUCTION {#S1}
============

Gallbladder cancer affects over 140,000 patients annually worldwide and over 100,000 will die each year from this disease.([@R1]) Women are affected more than men and in the U.S.; Hispanic population and Alaskan natives have a disproportionately high incidence of gallbladder cancer.([@R2]) There is a remarkable geographic variation with the highest incidence rates reported in India, Korea, Japan, Czech Republic, Slovakia, Spain, Columbia, Chile, Peru, Bolivia, and Ecuador. Etiologies include chronic cholelithiasias, *Salmonella* infections, toxin exposure, obesity and rarely due to genetic diseases like Hereditary Non-Polyposis Cancer Coli (HNPCC) and type 1 neurofibromatosis. Gallbladder cancer is thought to be at least partly the consequence of chronic inflammation-induced genetic changes.

The current molecular profiling data of gallbladder cancer are limited to small case series or case reports that include one or more oncogenes. High-throughput screening for targetable mutations in this disease is lacking. An understanding of the molecular characteristics and heterogeneity of gallbladder cancer is critical towards improving the treatment paradigm for this disease. An impetus for such characterization is the potential of targeted therapies directed against the products of these molecular aberrations including the tumor proteomic profile. Once the underlying molecular abnormalities of a cancer are identified, targeted inhibitors can be discovered and result in incremental benefit even in genetically heterogeneous malignancies. For instance, in lung cancer the identification of echinoderm microtubule associated protein like 4 - anaplastic lymphoma kinase (*EML4-ALK)* mutation has led to a targeted approach with crizotinib and tumors with epidermal growth factor receptor (*EGFR*) mutations to the development of erlotinib or gefitinib.([@R3]) High-throughput technologies that can rapidly screen for somatic mutations in archival formalin-fixed, paraffin-embedded specimens are critical for this effort. The Sequenom Massarray™ system is ideally suited for the detection of low abundance mutations and can be customized towards targeted therapeutics.([@R4], [@R5]) In the present study, we used the high-throughput Sequenom MassArray™ approach to investigate mutations in 33 genes in a cohort of gallbladder cancer cases to determine the frequency of genetic mutations in this population. We also explored next generation sequencing (NGS) to examine a wider panel of genetic aberrations in a limited number of gallbladder cancer cases.

MATERIAL AND METHODS {#S2}
====================

Tumor samples {#S3}
-------------

Surgically resected, formalin fixed paraffin embedded (FFPE) specimens were obtained for 72 patients with gallbladder cancer. The paraffin embedded blocks were sectioned, and hematoxylin & eosin (H&E) stained slides were reviewed by surgical pathology to confirm the tumor content in each section. Ten serial sections (4µm) were cut from selected tissue blocks and areas with tumor tissue were micro dissected from those slides using the H&E slides as templates. Approval for the study was obtained from the institutional review board at MD Anderson Cancer Center.

DNA Extraction {#S4}
--------------

The samples were deparaffinized using xylene washes followed by ethanol (100%) washes. DNA extraction was performed using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA) according to the manufacturer protocol. DNA was quantitated using the NanoQuant system (Tecan Group, Männedorf, Switzerland).

Sequenom MassArray {#S5}
------------------

Hotspot mutational analysis was performed using the Sequenom MassARRAY™ using the iPLEX™ technology (Sequenom, Inc, San Diego, CA). This technology allows for parallel high-throughput screening while using minimal DNA obtained from FFPE specimens ([@R6]). Mutations were screened by using amplification through polymerase chain reaction (PCR) and single-base primer extension where the wild type or mutated base was identified by mass spectrometry. Briefly, for each mutation site, PCR and extension primers were designed using Sequenom, Inc. Assay Design. PCR reactions were run following manufacture's protocol. After PCR, amplicons were cleaned using EXO-SAP^®^ kit (Sequenom) in a GeneAmp 9700 thermocycler (Applied Biosystems). Then the primer was then extended by IPLEX™ chemistry, desalted using Clean Resin (Sequenom), and spotted onto SpectroChip matrix chips (Sequenom) using a nanodispenser (Samsung). Chips were run in duplicate on a Sequenom MassArray Matrix-assisted laser desorption/ionization-Time of Flight (MALDI-TOF) MassArray system. We used Sequenom Typer Software for visual inspection and interpretation of mass spectra. Reactions where the mutant peak represented more than 10% of the wild type peak were scored as positive. The data analysis was performed using MassArray TYPER 4.0 genotyping software (Sequenom) where the SNP calls were divided in 3 groups: conservative, moderate and aggressive calls, depending on the level of confidence.

The Sequenom panel used here was previously designed by the Characterized Cell Line Core (Core Shared Resources -- CCSG) at MD Anderson Cancer Center with the aim of detecting somatic DNA alterations in cancer samples. The Sequenom panel was designed based on data form the Catalogue of Somatic Mutations in Cancer (COSMIC) and the Cancer Genome Atlas (TCGA) that reported those alterations (and others in the panel) as somatic mutations previously. A total of 159 point mutations in 33 genes frequently mutated in solid tumors including were analyzed. The analytical sensitivity of the assay \[limit of detection (LOD) 5%--10% of mutant DNA in total DNA\] is higher than conventional Sanger sequencing (LOD: 10%--20%) and similar to pyrosequencing (LOD: 5%--10%). The advantages offered by the MassARRAY system include high-throughput screening for many hot-spot mutations in parallel, use of minimal DNA isolated from formalin-fixed paraffin-embedded tissues, ability to detect coexisting multiple mutations, and cost and time effectiveness. [Appendix 1](#APP1){ref-type="app"} lists the genes and mutations investigated in this study.

Next Generation Sequencing {#S6}
--------------------------

The pathologic diagnosis of each case of gallbladder cancer was confirmed on routine hematoxylin- and eosin-stained slides. All samples sent for DNA extraction contained a minimum of 20% DNA derived from tumor cells. DNA was extracted from 40 mm of FFPE tissue using the Maxwell 16 FFPE Plus LEV DNA Purification kit (Promega™) and quantified using a standardized PicoGreen fluorescence assay (Invitrogen™). Library construction was performed as described previously, using 50--200 ng of DNA sheared by sonication to B100--400 bp before end-repair, dA addition and ligation of indexed, Illumina™ sequencing adaptors ([@R7], [@R8]). Enrichment of target sequences (3320 exons of 182 cancer-related genes and 37 introns from 14 genes recurrently rearranged in cancer representing approximately 1.1Mb of the human genome) was achieved by solution-based hybrid capture with a custom Agilent SureSelect™ biotinylated RNA baitset ([@R8]). The selected libraries were sequenced on an Illumina HiSeq 2000 platform using 49149 paired-end reads. Sequence data from genomic DNA was mapped to the reference human genome (hg19) using the Burrows-Wheeler Aligner™ and were processed using the publicly available Sequence Alignment/Map (SAMtools), Picard and Genome Analysis Toolkit ([@R9], [@R10]). Point mutations were identified by a Bayesian algorithm; short insertions and deletions determined by local assembly; gene copy number alterations (amplifications) by comparison to process matched normal controls; and gene fusions/rearrangements were detected by clustering chimeric reads mapped to targeted introns as described previously ([@R11]).

Statistical Analysis {#S7}
--------------------

Given the limited number of cases analyzed for NGS, only the cases analyzed for hotspot mutations (n=57) were analyzed for their association with survival. Overall survival (OS) was calculated as the number of months from surgery (or core biopsy) to death or last follow-up date. Patients who were alive at their last follow-up were censored on that date. Time to Progression (TTP) was calculated as the number of months from surgery (or core biopsy) to progression. Patients without tumor progression at their last follow-up were censored on that date. The Kaplan-Meier product limit method was used to estimate the median OS for each clinical/demographic factor.([@R12]) Univariate Cox proportional hazards regression was used to model the association between potential predictors and OS. Multivariate Cox proportional hazards regression was used to model all the statistically significant variables in the univariate setting. Backwards selection method was used to remove variables that did not remain significant in the multivariate model.([@R13]) For each factor, medians, hazard ratios (HR), their 95% confidence intervals (CI), and proportional hazards regression p-values are presented in tables. Similar analyses were performed for time to progression. Statistical significance was considered at P-values of \<0.05.

Statistical analysis was performed using STATA/SE version 12.1 statistical software (Stata Corp. LP, College Station, TX).

RESULTS {#S8}
=======

Fifty-seven cases of gallbladder cancer were analyzed for hotspot mutations and 15 for NGS. Patient demographics are described in [Table 1](#T1){ref-type="table"}. Fourteen hotspot mutations ([Table 2](#T2){ref-type="table"}) were identified from eleven different tumors within this sample set, with three cases demonstrating more than 1 mutation. *IDH1* mutations were the most frequent (n=4). The others identified included mutations of *KRAS* (n=3), *NRAS* (n=3), *PIK3CA* (n=2) and *MET* (n=1). Of these, *IDH1* and *MET* may represent germline polymorphisms rather than somatic mutations as discussed below. [Figure 1](#F1){ref-type="fig"} demonstrates the *PIK3CA, IDH1 and KRAS* mutations. [Figures 2A--2D](#F2){ref-type="fig"} depict the histologies (H&E) of four gallbladder cancer cases along with their corresponding mutations. A total of 36/57 (63.2%) patients enrolled in the study have expired to date. A univariate survival analysis on these data demonstrated a significant relationship of overall survival with six factors. The overall risk of mortality was associated with treatment with chemotherapy (HR: 2.84; 95%CI: 1.23--6.53; p=0.014), lymphatic infiltration (HR: 2.72; 95%CI: 1.22--6.04; p=0.014), venous infiltration (HR: 2.27; 95%CI: 1.08--4.79; p=0.031), perineural infiltration (HR: 2.14; 95%CI: 1.06--4.33; p=0.033), positive *KRAS* mutation (HR: 3.56; 95%CI: 1.06--11.92; p=0.040), and with a positive *IDH1* mutation (HR: 4.04; 95%CI: 1.35--12.13; p=0.013) ([Fig.3a](#F3){ref-type="fig"}). In addition, patients who had chemotherapy were at greater risk of progressing than non-treated patients (HR: 13.82; 95%CI: 1.84--103.84; p=0.011).

A multivariate analysis of overall survival was also performed using backward elimination methods. Overall survival was seen to be associated with patients age 62--79 (HR: 5.93; 95%CI: 1.76 -- 20.00; p=0.004), and age ≥ 70 (HR: 3.84; 95%CI: 1.19 -- 12.39; p=0.024), clinical stages 3a, 3b, 4a & 4b (HR: 2.60; 95%CI: 1.03--6.59; p=0.044), venous infiltration (HR: 3.42; 95%CI: 1.46--8.03; p=0.005) and *KRAS* (HR: 8.91; 95%CI: 1.99--39.94; p=0.004-[Fig.3b](#F3){ref-type="fig"}).

On NGS, 26 mutations were noted in 15 cases ([Tables 3](#T3){ref-type="table"}). *P53* was most common and there was relative preponderance of mutations involving the PI3 kinase pathway: *STK11, RICTOR, TSC2*. Two cases had FGF pathway aberrations: FGF10 amplification and one case of *FGF3-TACC* fusion gene ([Fig 4](#F4){ref-type="fig"}). Two cases are illustrated wherein the mutational data were utilized for targeted therapeutics with success ([Fig 5a](#F5){ref-type="fig"}; [Fig 5b](#F5){ref-type="fig"}).

DISCUSSION {#S9}
==========

Gallbladder cancer has been referred to as an 'orphan' cancer, given its relative infrequency in the Western population. Molecular research in this disease has lagged behind the commoner gastrointestinal cancers, such as colorectal and gastric cancer. The known genetic alterations include mutations of *K-RAS* (in 3--40%, more likely in East Asia), *PI3KCA* (12%), *p53* (40%) and *BRAF* (33%) oncogenes, and amplification of *Her-2/ Neu* (15%).([@R14], [@R15]) Other genetic alterations described include loss of expression fragile histidine triad (*FHIT*) gene, microsatellite instability, overexpression of P13-K/Akt, VEGF and p21.([@R16], [@R17]) Key limitations of the above data include the small number of cases tested, geographic and ethnic variation.

The present study, to our knowledge represents the largest number of surgically resected gallbladder cancer cases that had somatic mutation profiling. All of our specimens were FFPE and therefore we chose a platform that had non-fastidious DNA requirements and could detect low-abundance mutations. Sequenom Massarray technique is ideal in this situation for profiling single nucleotide mutations and polymorphisms. A limitation of this retrospective study is that we did not have parallel blood or normal tissue to assess if the mutations we noted were germline or somatic. We have used preselected panels, which included targetable oncogenes from the COSMIC and TCGA database. While the plan was to include somatic mutations only, in these panels, subsequent studies have reported that at least two of the genetic alterations (*IDH1* and *met*) were germline.

Sanger sequencing has been effectively used for somatic mutation discovery. However, when there is a heterogeneous mixture of cancerous and normal tissue, Sanger sequencing may be unable to detect low frequency mutations. In one published study, sequencing failed to detect *EGFR* (Epidermal Growth Factor Receptor) mutations in tumors with roughly 10% allele frequencies.([@R18]) Clinical somatic mutation detection will require high degree of sensitivity than standard sequencing. The Massarray™ system combines PCR with matrix-assisted laser desorption/ ionization time of flight mass spectrometry for rapidly multiplexed nucleic acid analysis. Furthermore, this system can rapidly profile hundreds of mutations in FFPE samples with as little as 5% mutation abundance with a short turn-around time. However, the podisadvantages of this approach is that these multiplex genomic tests only detect the expression of pre-selected hotspot mutations and do not lead to the discovery of novel targets. This limitation is particularly relevant to the less common tumors, such as gallbladder cancer.

Our findings indicated that *IDH1_V178I* was the commonest DNA variation on Sequenom Massarray. It is estimated that another mutation on *IDH1_R132* occurs in upto 20% of high grade glioma and this mutation is associated with a better prognosis and response to therapy.([@R19]) On the other hand, the same somatic mutation in acute myeloid leukemia is associated with a poor prognosis and lack of complete response, particularly in otherwise cytogenetically normal cases.([@R20]) A poor prognosis was noted in our study with *IDH1_V178I* mutation. In a prior study, *IDH1* mutations (*IDH1_R132)* were noted in cholangiocarcinoma, but none were noted in the 25 cases of gallbladder cancer studied. ([@R21]) Isocitrate dehydrogenase (IDH) catalyzes the conversion of isocitrate to α-ketoglutarate and mutations in this pathway is a relevant target for therapy given the development of IDH inhibitors.([@R22]) These mutations also conferred an enzymatic gain-of-function: the novel NADPH-dependent reduction of α-ketoglutarate to the normally trace metabolite *R*(−)-2-hydroxyglutarate (2-HG), which is oncogenic.([@R23]) Measurement of intracellular 2-HG can therefore be used to assess the functional impact of the mutation. In case of *IDH1_V178I*, no elevation of 2-HG was noted, which raises the question of whether this mutation represents a non-functional polymorphism or if the functional oncogenic effect includes a non 2-HG metabolic pathway. Several SNPs related to the lipid metabolism, estrogen receptor and DNA repair have been associated with survival in gallbladder cancer ([@R24]--[@R26]). One case had *ALK* mutation (*ALK_F1174L_C3522AG*), which has not yet been described in this disease and offers effective targeted therapy options.

The next generation sequencing approach offers several advantages over the traditional methods, including the ability to simultaneously sequence hundreds of genes in a single test, have a higher depth of coverage and thereby heightened sensitivity for mutation detection, ideal for 'precision medicine'.([@R27]) In addition, these technologies can detect deletions, amplifications, translocations and base substitutions at a relatively rapid rate. The disadvantage includes cost, high computational requirements and high tissue requirement that make the technology unsuitable for smaller biopsies, circulating tumor cells and circulating plasma DNA. A notable finding in our study was the relatively common occurrence PI3-kinase pathway mutations (*TCS2, STK11, RICTOR*), which opens potential options for targeted therapies directed against these proteins. Deshpande *et al*, had noted the relative frequency of *PI3KCA* mutations in this population.([@R21]) Other targetable mutations included *AURKA and BAP*, which may potentially be treated with aurora kinase inhibitors and DNA damaging agents \[such as cisplatin and poly ADP ribose polymerase (PARP) inhibitors\], respectively.

A novel finding in our study was the detection of fusion between Fibroblast Growth Factor Receptor (*FGFR3)* and Transforming Acidic Coiled-Coil *(TACC)* \[in-frame fusion between exons 1--17 of *FGFR3* (containing the kinase domain) and exons 11 to the C-terminus of *TACC3* (containing the coiled coil TACC domain)\]. The FGFR family plays an important role in cellular proliferation and angiogenesis and gain of function mutations in FGFRs have been reported in several malignancies.([@R28]) *FGFR3* mutation or amplification has not been reported in gallbladder cancer to our knowledge. Similar fusions between *FGFR3* and *TACC3* have recently been reported in a small percentage of glioblastomas.([@R29]) These fusions have also recently been described in cholangiocarcinoma, are proven to be oncogenic and the resulting tumors may be susceptible to FGFR inhibitors.([@R30])

In conclusion, gallbladder cancer is amenable to precise interventions with targeted therapies and novel sequencing techniques may provide prognostic and therapeutic opportunities.
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###### 

GENES AND MUTATIONS INVESTIGATED

  ------------------------- ---------------------- --------------------------
  AKT1_E17K_G49A            FGFR1_S125L_C374T      MET_Y1248C_A3743G
  AKT2_E17K_G49A            FGFR2_N549KK_T1647GA   MET_Y1248HD_T3742CG
  AKT3_E17K_G49A            FGFR2_S252W_C755G      MET_Y1253D_T3757G
  ALK_F1174CS_T3521GC       FGFR3_G370C_G1108T     MGA_T1747N_C5421A
  ALK_F1174L_C3522AG        FGFR3_G380R_G1138A     NRAS_A146T_G436A
  ALK_F1174LIV_T3520CAG     FGFR3_G697C_G2089T     NRAS_G12DAV_G35ACT
  ALK_F1245C_T3734G         FGFR3_K650MT_A1949TC   NRAS_G12SRC_G34ACT
  ALK_F1245L_C3735AG        FGFR3_R248C_C742T      NRAS_G13DAV_G38ACT
  ALK_F1245VI_T3733GA       FGFR3_S249C_C746G      NRAS_G13SRC_G37ACT
  ALK_I1171N_T3512A         FGFR3_Y373C_A1118G     NRAS_Q61EKX_C181GAT
  ALK_R1275QL_G3824AT       FOXL2_C134W_C402G      NRAS_Q61HHQ_A183TCG
  BCOR_N1407STI_A4220GCT    GNA11_Q209LP_A626TC    NRAS_Q61RPL_A182GCT
  BRAF_D594GV_A1781GT       GNA11_R183C_C547T      PDGFRA_D842V_A2525T
  BRAF_E586K_G1756A         GNAQ_Q209H_A627T       PDGFRA_D842YN_G2524TA
  BRAF_G464EVA_G1391ATC     GNAQ_Q209LPR_A626TCG   PDGFRA_N659K_C1977A
  BRAF_G466EVA_G1397ATC     GNAS_R201H_G602A       PDGFRA_N659Y_A1975T
  BRAF_G466R_G1396CA        GNAS_R201SC_C601AT     PDGFRA_V561D_T1682A
  BRAF_G469EVA_G1406ATC     GRM3_E870K_G2608A      PIK3CA_A1046V_C3137T
  BRAF_G469R_G1405CA        IDH1_G70D_G209A        PIK3CA_C420R_T1258C
  BRAF_K601E_A1801G         IDH1_R132CGS_C394TGA   PIK3CA_E110K_G328A
  BRAF_L597RQ_T1790GA       IDH1_R132HL_G395AT     PIK3CA_E418K_G1252A
  BRAF_V600_G1800           IDH1_V178I_G532A       PIK3CA_E453K_G1357A
  BRAF_V600EAG_T1799ACG_F   IDH2_R140LQ_G419TA     PIK3CA_E542KQ_G1624AC
  BRAF_V600EAG_T1799ACG_R   IDH2_R140W_C418T       PIK3CA_E542VG_A1625TG
  BRAF_V600LM_G1798TA       IDH2_R172GW_A514GT     PIK3CA_E545AGV_A1634CGT
  CC2D1A_L913V_C3036G       IDH2_R172MK_G515TA     PIK3CA_E545D_G1635CT
  CDK4_R24C_C70T            IDH2_R172S_G516T       PIK3CA_E545KQ_G1633AC
  CDK4_R24H_G71A            JAK2_V617F_G1849T      PIK3CA_F909L_C2727G
  CSMD1_A409S_G1225T        KIT_D816GVA_A2447GTC   PIK3CA_G118D_G353A
  CSMD1_Q3005X_C9013T       KIT_D816HNY_G2446CAT   PIK3CA_H1047RL_A3140GT_F
  CTNNB1_D32AGV_A95CGT      KIT_K642E_A1924G       PIK3CA_H1047RL_A3140GT_R
  CTNNB1_D32HNY_G94CAT      KIT_L576P_T1727C       PIK3CA_H1047Y_C3139T
  CTNNB1_G34EVA_G101ATC     KIT_N566D_A1696G       PIK3CA_H701P_A2102C
  CTNNB1_H36PRY_A107CGT     KIT_N822KNK_T2466GCA   PIK3CA_K111N_G333C
  CTNNB1_I35NST_T104AGC     KIT_N822YHD_A2464TCG   PIK3CA_M1043I_G3129ATC
  CTNNB1_S33APT_T97GCA      KIT_R634W_C1900T       PIK3CA_M1043V_A3127G
  CTNNB1_S37CFY_C110GTA     KIT_V559ADG_T1676CAG   PIK3CA_N345K_T1035A
  CTNNB1_S45APT_T133GCA     KIT_V560DGA_T1679AGC   PIK3CA_P539R_C1616G
  CTNNB1_S45CFY_C134GTA     KIT_V825A_T2474C       PIK3CA_Q060K_C178A
  CTNNB1_T41APS_A121GCT     KIT_Y553N_T1657A       PIK3CA_Q546EK_C1636GA
  CTNNB1_T41INS_C122TAG     KRAS_A146PT_G436CA     PIK3CA_Q546LPR_A1637TCG
  EGFR_G719CS_G2155TA       KRAS_G10R_G28A         PIK3CA_R088Q_G263A
  EGFR_K860I_A2579T         KRAS_G12DAV_G35ACT     PIK3CA_S405F_C1214T
  EGFR_L858R_T2573G         KRAS_G12SRC_G34ACT     PIK3CA_T1025SA_A3073TG
  EGFR_L861QR_T2582AG       KRAS_G13DAV_G38ACT     PIK3CA_Y1021C_A3062G
  EGFR_S720P_T2158C         KRAS_G13SRC_G37ACT     PIK3CA_Y1021HN_T3061CA
  EGFR_T790M_C2369T         KRAS_Q61EKX_C181GAT    PPP2R1A_W257G_T769G
  EGFR_T854I_C2561T         KRAS_Q61HHQ_A183CTG    RAF1_A319S_G955T
  EGFR_Y813C_A2438G         KRAS_Q61LPR_A182TCG    RAF1_L613V_C1837G
  EPHA3_K761NN_G2283TC      MAP2K2_E207KQ_G619AC   RAF1_N115S_A344G
  FBXO4_L23Q_T68A           MAP2K7_D290D_C870T     RAF1_Q335H_G1005C
  FBXO4_P76T_C226A          MAP2K7_R162H_G485A     RAF1_S259A_T775G
  FBXO4_S8R_C24AG           MAP2K7_S271T_T811A     RAF1_Y340D_T1018G
  FBXW7_R465C_C1393T        MAP2K7_S311L_C932T     RET_M918T_T2753C
  FBXW7_R465HL_G1394AT      MET_H1112RL_A3335GT    RPL22_K15TRM_A44CGT
  FBXW7_R479QL_G1436AT      MET_H1112Y_C3334T      SFRS9_Y192X_C722A
  FBXW7_R505CS_C1513TA      MET_M1268T_T3803C      SMO_A324T_G970A
  FBXW7_R505HLP_G1514ATC    MET_N375S_A1124G       SRC_Q531X_C1591T
  FBXW7_S582L_C1745T        MET_R988C_C2962T       TGM2_S212P_T734C
  FGFR1_P252T_C754A         MET_T1010I_C3029T      
  ------------------------- ---------------------- --------------------------

###### 

GENETIC MUTATIONS SEQUENCED USING NGS

  --------------------------------------------------- ---------- ---------- ---------- ----------
  182 genes sequenced across entire coding sequence                                    
  **Gene**                                            **Gene**   **Gene**   **Gene**   **Gene**
  ABL1                                                CDK6       FLT4       MEN1       PTPN11
  ABL2                                                CDK8       FOXP4      MET        PTPRD
  AKT1                                                CDKN2A     GATA1      MITF       RAF1
  AKT2                                                CDKN2B     GNA11      MLH1       RARA
  AKT3                                                CDKN2C     GNAQ       MLL        RB1
  ALK                                                 CEBPA      GNAS       MPL        RET
  APC                                                 CHEK1      GPR124     MRE11A     RICTOR
  AR                                                  CHEK2      GUCY1A2    MSH2       RPTOR
  ARAF                                                CRKL       HQXA3      MSH6       RUNX1
  ARFRP1                                              CRLF2      HRAS       MTOR       SMAD2
  ARID1A                                              CTNNB1     HSP9OAA1   MUTYI-1    SMAD3
  ATM                                                 DDR2       IDH1       MYC        SMAD4
  ATR                                                 DNMT3A     IDH2       MYCL1      SMARCA4
  AURKA                                               DOT1L      IGF1R      MYCN       SMARCB1
  AURKS                                               EGFR       IGF2R      NFl        SMO
  BAP1                                                EPI-1A3    IKBKE      NF2        SOX1O
  BCL2                                                EPF-1A5    IKZF1      NKX2-1     SOX2
  BCL2A1                                              EPHA6      INHBA      NOTCH1     SRC
  BCL2L1                                              EPHA7      INSR       NPM1       STAT3
  BCL2L2                                              EPHB1      IRS2       NRAS       STK11
  BCL6                                                EPHB4      JAK1       NTRK1      SUFU
  BRAF                                                EPHB6      JAK2       NTRK2      T5X22
  BRCA1                                               ERBB2      JAK3       NTRK3      TET2
  BRCA2                                               ERBB3      JUN        PAK3       TGFBR2
  CARD11                                              ERBB4      KDM6A      PAX5       TNFAIP3
  CBL                                                 ERCC2      KDR        PDGFRA     TNKS
  CCND1                                               ERG        KIT        PDGFRB     TNKS2
  CCND2                                               ESR1       KRAS       PHLPP2     TOP1
  CCND3                                               EZH2       LRP1B      PIK3CA     TP53
  CCNE1                                               FANCA      LRP6       PIK3CG     TSC1
  CD79A                                               FBXW7      LTK        PIK3R1     TSC2
  CD79B                                               FGFR1      MAP2K1     PKHD1      USP9X
  CDH1                                                FGFR2      MAP2K2     PLCG1      VHL
  CDH2                                                FGFR3      MAP2K4     PRKDC      WT1
  CDH2O                                               FGFR4      MCL1       PTCH1      
  CDH5                                                FLT1       MDM2       PTCH2      
  CDK4                                                FLT3       MDM4       PTEN       
  14 genes sequenced across selected iritrons                                          
  **Gene**                                                                             
  ALK                                                                                  
  BCR                                                                                  
  BRAF                                                                                 
  EGFR                                                                                 
  ETV1                                                                                 
  ETV4                                                                                 
  ETV5                                                                                 
  ETV6                                                                                 
  EWSR1                                                                                
  MLL                                                                                  
  RAF1                                                                                 
  RARA                                                                                 
  RET                                                                                  
  TMPRSS2                                                                              
  --------------------------------------------------- ---------- ---------- ---------- ----------

![Peaks for PIK3CA, IDH1 and KRAS mutations (Sequenom Massarray)](nihms660933f1){#F1}

![2a) IDH1 mutation and association with overall survival.\
2b) KRAS mutation and association with overall survival](nihms660933f2){#F2}

![Schematic of FGFR3-TACC3 Fusion Gene in Gallbladder Cancer](nihms660933f3){#F3}

![Illustrations of mutational data successfully utilized for targeted therapeutics.\
4a) Erlotinib in combination with gemcitabine and oxaliplatin before therapy and 4 months post therapy.\
4b) Trastuzumab in combination with 5-fluorouracil, leucovorin and oxaliplatin as second-line therapy before therapy and 3 months post-therapy.](nihms660933f4){#F4}

![Representative histopathology of samples with corresponding mutations used for Sequenom analysis and NGS.\
5A) KRAS\
5B) TP53, ERBB2\
5C) FGFR3-TACC3, CCNE1, MCL1, MYC, TP53\
5D)ARID1A](nihms660933f5){#F5}

###### 

Summary Statistics of Patient Demographics and Tumor Characteristics

  CHARACTERISTICS                                           Type of Analysis   
  --------------------------------------------------------- ------------------ -----------
  Sex                                                                          
    Male                                                    25 (44%)           5 (33%)
    Female                                                  32 (56%)           10 (67%)
                                                                               
  Ethnicity                                                                    
    Asian                                                   1 (2%)             1 (7%)
    Hispanic                                                8 (14%)            1 (7%)
    Black                                                   5 (9%)             0 (0%)
    White                                                   43 (75%)           13 (86%)
                                                                               
  Type of Surgery                                                              
    None                                                    3 (5%)             4 (27%)
    Simple (Laparoscopic)                                   31 (54%)           6 (40%)
    Radical                                                 23 (41%)           5 (33%)
                                                                               
  Adjuvant Therapy                                                             
    Chemotherapy                                            25 (44%)           13 (87%)
    Chemotherapy & Radiation                                11 (19%)           2 (13%)
    None                                                    21 (37%)           0 (0%)
                                                                               
  Histological Type                                                            
    Adenocarcinoma                                          51 (90%)           15 (100%)
    Adenosquamous                                           4 (7%)             0 (0%)
    Carcinosarcoma                                          2(3%)              0 (0%)
                                                                               
  Degree of Differentiation                                                    
    Poor                                                    16 (28%)           7 (47%)
    Moderate                                                38 (67%)           6 (40%)
    Well                                                    2 (4%)             2 (13%)
    N/A                                                     1 (2%)             0 (0%)
                                                                               
  Lymphatic Infiltration[\*](#TFN2){ref-type="table-fn"}                       
    No                                                      21 (39%)           1 (10%)
    Yes                                                     33 (61%)           9 (90%)
                                                                               
  Venous Infiltration[\*](#TFN2){ref-type="table-fn"}                          
    No                                                      22 (41%)           1 (10%)
    Yes                                                     32 (59%)           9 (90%)
                                                                               
  Perineural Infiltration[\*](#TFN2){ref-type="table-fn"}                      
    No                                                      29 (54%)           3 (30%)
    Yes                                                     25 (46%)           7 (70%)

N=Patient numbers;

Surgical samples only (Hotspot N=54, NGS N=10)

###### 

Genetic Mutations identified through Hotspot Analysis

  --------------------------------------------------------------------------------
  Sample ID   Histology        Mutations
  ----------- ---------------- ---------------------------------------------------
  13          Adenocarcinoma   IDH1_V178I_G532A[\*](#TFN3){ref-type="table-fn"}\
                               PIK3CA_H1047RL_A3140GT

  26          Adenosquamous    KRAS_G12DAV_G35ACT\
                               NRAS_Q61RPL_A182GCT

  32          Adenocarcinoma   IDH1_V178I_G532A[\*](#TFN3){ref-type="table-fn"}

  34          Adenocarcinoma   NRAS_G12DAV_G35ACT

  42          Adenocarcinoma   IDH1_V178I_G532A[\*](#TFN3){ref-type="table-fn"}

  44          Adenocarcinoma   KRAS_G12DAV_G35ACT\
                               MET_N375S_A1124G[\*](#TFN3){ref-type="table-fn"}

  46          Adenocarcinoma   KRAS_G13DAV_G38ACT

  47          Adenocarcinoma   IDH1_V178I_G532A[\*](#TFN3){ref-type="table-fn"}

  49          Adenocarcinoma   PIK3CA_M1043I_G3129ATC

  56          Adenocarcinoma   ALK_F1174L_C3522AG

  57          Adenocarcinoma   NRAS_G12DAV_G35ACT
  --------------------------------------------------------------------------------

Most likely to represent genomic variation (SNP)

###### 

Genetic Alterations Identified Through NGS (N=15)

  -----------------------------------------------------------------
  GENE         Alterations (With allele frequency or copy number)
  ------------ ----------------------------------------------------
  TP53         V274F (10%)\
               R282G (50%)\
               R213\* (29%)\
               Y220C (2%)\
               R342\* (24%)\
               C141\* (21%)\
               Splice site 559+1G\>T (21%)\
               F109V (46%)\
               V272L

  STK11        R86\* (11%)\
               E120\* (15%)\
               K62fs\*98 (6%)

  CCNE1        Amplification (copy no 11×)\
               Amplification (copy no 13×)

  MDM2         Amplification (copy no 6×)\
               Amplification (copy no 16×)

  MYC          Amplification (copy no 12×)\
               Amplification (copy no 7×)

  RICTOR       Amplification (copy no 12×)\
               Amplification (copy no 7×)

  APC          S2113fs\*25 (21%)

  ARID1A       G284fs\*78 (18%)

  AURKA        S398L (48%)

  CDKN2A       Truncation - exon 1

  CDKN2A/B     Loss\
               Loss

  CRKL         Amplification (copy no 12×)

  FGF10        Amplification (copy no 7×)

  FGFR3-TACC   FGFR3-TACC3 fusion, Amplification (copy no 8×)

  KRAS         G12C, 3%

  MCL1         Amplification (copy no 8×)\
               Amplification (copy no 8×)

  PRKAR1A      R97\* (33%)

  SMAD4        Truncation

  SMARCA4      D558fs\*6 (26%)

  TSC2         Loss

  BAP1         splice site 438-1delGTTTTTCCCC AG, 10%\
               1delGTTTTTCCCC AG, 10%

  ERBB2        Amplification (copy no 20×)\
               Amplification (copy no 9×)

  PIK3CA       Amplification (copy no 7×)

  ZNF703       Amplification (copy no 7×)
  -----------------------------------------------------------------
